nodes	percent_of_prediction	percent_of_DWPC	metapath
Bexarotene—RXRA—thyroid cancer	0.747	1	CbGaD
Bexarotene—CYP2C9—Sorafenib—thyroid cancer	0.00593	0.345	CbGbCtD
Bexarotene—CYP3A4—Vandetanib—thyroid cancer	0.00572	0.333	CbGbCtD
Bexarotene—RXRG—RXR and RAR heterodimerization with other nuclear receptor—THRB—thyroid cancer	0.0038	0.0468	CbGpPWpGaD
Bexarotene—RXRB—RXR and RAR heterodimerization with other nuclear receptor—THRB—thyroid cancer	0.00357	0.044	CbGpPWpGaD
Bexarotene—CYP3A4—Sorafenib—thyroid cancer	0.00345	0.201	CbGbCtD
Bexarotene—RXRG—Regulation of Androgen receptor activity—TRIM24—thyroid cancer	0.00333	0.0411	CbGpPWpGaD
Bexarotene—RXRB—Vitamin D Metabolism—RXRA—thyroid cancer	0.00326	0.0402	CbGpPWpGaD
Bexarotene—RXRB—Regulation of Androgen receptor activity—TRIM24—thyroid cancer	0.00313	0.0387	CbGpPWpGaD
Bexarotene—RXRG—Nuclear Receptors—THRB—thyroid cancer	0.0028	0.0346	CbGpPWpGaD
Bexarotene—RXRB—Nuclear Receptors—THRB—thyroid cancer	0.00263	0.0325	CbGpPWpGaD
Bexarotene—RXRG—Nuclear Receptor transcription pathway—THRB—thyroid cancer	0.00221	0.0273	CbGpPWpGaD
Bexarotene—CYP3A4—Doxorubicin—thyroid cancer	0.00209	0.122	CbGbCtD
Bexarotene—RXRB—Nuclear Receptor transcription pathway—THRB—thyroid cancer	0.00208	0.0257	CbGpPWpGaD
Bexarotene—RXRG—a6b1 and a6b4 Integrin signaling—LAMA2—thyroid cancer	0.00199	0.0246	CbGpPWpGaD
Bexarotene—RXRB—a6b1 and a6b4 Integrin signaling—LAMA2—thyroid cancer	0.00188	0.0231	CbGpPWpGaD
Bexarotene—RXRA—RXR and RAR heterodimerization with other nuclear receptor—THRB—thyroid cancer	0.00186	0.0229	CbGpPWpGaD
Bexarotene—RXRA—Regulation of Androgen receptor activity—TRIM24—thyroid cancer	0.00163	0.0201	CbGpPWpGaD
Bexarotene—RXRG—RXR and RAR heterodimerization with other nuclear receptor—RXRA—thyroid cancer	0.00161	0.0199	CbGpPWpGaD
Bexarotene—RXRG—Retinoic acid receptors-mediated signaling—CDK1—thyroid cancer	0.00155	0.0191	CbGpPWpGaD
Bexarotene—RXRB—RXR and RAR heterodimerization with other nuclear receptor—RXRA—thyroid cancer	0.00152	0.0187	CbGpPWpGaD
Bexarotene—RXRB—Retinoic acid receptors-mediated signaling—CDK1—thyroid cancer	0.00146	0.018	CbGpPWpGaD
Bexarotene—RXRG—Retinoic acid receptors-mediated signaling—RXRA—thyroid cancer	0.00144	0.0177	CbGpPWpGaD
Bexarotene—RXRA—Nuclear Receptors—THRB—thyroid cancer	0.00137	0.0169	CbGpPWpGaD
Bexarotene—RXRB—Retinoic acid receptors-mediated signaling—RXRA—thyroid cancer	0.00135	0.0167	CbGpPWpGaD
Bexarotene—RXRG—Nuclear Receptors—RXRA—thyroid cancer	0.00119	0.0147	CbGpPWpGaD
Bexarotene—RXRB—Nuclear Receptors—RXRA—thyroid cancer	0.00112	0.0138	CbGpPWpGaD
Bexarotene—RXRA—Nuclear Receptor transcription pathway—THRB—thyroid cancer	0.00108	0.0134	CbGpPWpGaD
Bexarotene—RXRG—Vitamin A and Carotenoid Metabolism—RXRA—thyroid cancer	0.00108	0.0133	CbGpPWpGaD
Bexarotene—RXRG—a6b1 and a6b4 Integrin signaling—RXRA—thyroid cancer	0.00104	0.0128	CbGpPWpGaD
Bexarotene—RXRG—RXR and RAR heterodimerization with other nuclear receptor—PPARG—thyroid cancer	0.00102	0.0126	CbGpPWpGaD
Bexarotene—RXRB—Vitamin A and Carotenoid Metabolism—RXRA—thyroid cancer	0.00101	0.0125	CbGpPWpGaD
Bexarotene—RXRA—a6b1 and a6b4 Integrin signaling—LAMA2—thyroid cancer	0.000977	0.0121	CbGpPWpGaD
Bexarotene—RXRB—a6b1 and a6b4 Integrin signaling—RXRA—thyroid cancer	0.000977	0.0121	CbGpPWpGaD
Bexarotene—RXRB—RXR and RAR heterodimerization with other nuclear receptor—PPARG—thyroid cancer	0.000957	0.0118	CbGpPWpGaD
Bexarotene—RXRG—Nuclear Receptor transcription pathway—RXRA—thyroid cancer	0.000941	0.0116	CbGpPWpGaD
Bexarotene—RXRG—Regulation of Androgen receptor activity—RXRA—thyroid cancer	0.000912	0.0113	CbGpPWpGaD
Bexarotene—RXRB—Nuclear Receptor transcription pathway—RXRA—thyroid cancer	0.000884	0.0109	CbGpPWpGaD
Bexarotene—RXRB—Regulation of Androgen receptor activity—RXRA—thyroid cancer	0.000858	0.0106	CbGpPWpGaD
Bexarotene—RXRA—PPAR Alpha Pathway—CDK1—thyroid cancer	0.000851	0.0105	CbGpPWpGaD
Bexarotene—RXRA—Retinoic acid receptors-mediated signaling—CDK1—thyroid cancer	0.000759	0.00937	CbGpPWpGaD
Bexarotene—RXRG—Nuclear Receptors—PPARG—thyroid cancer	0.000751	0.00927	CbGpPWpGaD
Bexarotene—RXRA—The citric acid (TCA) cycle and respiratory electron transport—NDUFA13—thyroid cancer	0.000722	0.00891	CbGpPWpGaD
Bexarotene—RXRB—Nuclear Receptors—PPARG—thyroid cancer	0.000707	0.00872	CbGpPWpGaD
Bexarotene—RXRG—Nuclear Receptor transcription pathway—PPARG—thyroid cancer	0.000594	0.00733	CbGpPWpGaD
Bexarotene—RXRA—Transcription factor regulation in adipogenesis—PPARG—thyroid cancer	0.00057	0.00704	CbGpPWpGaD
Bexarotene—RXRB—Nuclear Receptor transcription pathway—PPARG—thyroid cancer	0.000558	0.00689	CbGpPWpGaD
Bexarotene—RXRG—Generic Transcription Pathway—TRIM33—thyroid cancer	0.000529	0.00653	CbGpPWpGaD
Bexarotene—RXRA—RXR and RAR heterodimerization with other nuclear receptor—PPARG—thyroid cancer	0.000499	0.00616	CbGpPWpGaD
Bexarotene—RXRB—Generic Transcription Pathway—TRIM33—thyroid cancer	0.000497	0.00614	CbGpPWpGaD
Bexarotene—CYP2C9—Arachidonic acid metabolism—HPGD—thyroid cancer	0.000484	0.00597	CbGpPWpGaD
Bexarotene—RXRG—Adipogenesis—RXRA—thyroid cancer	0.000445	0.00549	CbGpPWpGaD
Bexarotene—CYP3A4—Liver X Receptor Pathway—RXRA—thyroid cancer	0.000418	0.00516	CbGpPWpGaD
Bexarotene—RXRG—Generic Transcription Pathway—THRB—thyroid cancer	0.000382	0.00472	CbGpPWpGaD
Bexarotene—RXRA—Nuclear Receptors—PPARG—thyroid cancer	0.000368	0.00454	CbGpPWpGaD
Bexarotene—RXRB—Generic Transcription Pathway—THRB—thyroid cancer	0.00036	0.00444	CbGpPWpGaD
Bexarotene—RXRG—Retinoic acid receptors-mediated signaling—AKT1—thyroid cancer	0.000359	0.00443	CbGpPWpGaD
Bexarotene—RXRA—PPAR Alpha Pathway—CCND1—thyroid cancer	0.000355	0.00438	CbGpPWpGaD
Bexarotene—RXRB—Retinoic acid receptors-mediated signaling—AKT1—thyroid cancer	0.000338	0.00416	CbGpPWpGaD
Bexarotene—RXRG—Adipogenesis—HIF1A—thyroid cancer	0.00033	0.00408	CbGpPWpGaD
Bexarotene—RXRA—Circadian Clock—HIF1A—thyroid cancer	0.000322	0.00398	CbGpPWpGaD
Bexarotene—RXRG—a6b1 and a6b4 Integrin signaling—HRAS—thyroid cancer	0.000294	0.00363	CbGpPWpGaD
Bexarotene—RXRA—Nuclear Receptor transcription pathway—PPARG—thyroid cancer	0.000291	0.00359	CbGpPWpGaD
Bexarotene—RXRG—Adipogenesis—PPARG—thyroid cancer	0.000281	0.00347	CbGpPWpGaD
Bexarotene—RXRB—a6b1 and a6b4 Integrin signaling—HRAS—thyroid cancer	0.000276	0.00341	CbGpPWpGaD
Bexarotene—RXRG—a6b1 and a6b4 Integrin signaling—AKT1—thyroid cancer	0.00026	0.0032	CbGpPWpGaD
Bexarotene—RXRA—Generic Transcription Pathway—TRIM33—thyroid cancer	0.000259	0.0032	CbGpPWpGaD
Bexarotene—RXRG—Gene Expression—TRIM33—thyroid cancer	0.000255	0.00314	CbGpPWpGaD
Bexarotene—CYP3A4—Farnesoid X Receptor  Pathway—RXRA—thyroid cancer	0.00025	0.00309	CbGpPWpGaD
Bexarotene—CYP2C9—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.00025	0.00308	CbGpPWpGaD
Bexarotene—RXRB—a6b1 and a6b4 Integrin signaling—AKT1—thyroid cancer	0.000244	0.00301	CbGpPWpGaD
Bexarotene—RXRG—Generic Transcription Pathway—MEN1—thyroid cancer	0.000243	0.003	CbGpPWpGaD
Bexarotene—RXRB—Gene Expression—TRIM33—thyroid cancer	0.000239	0.00295	CbGpPWpGaD
Bexarotene—RXRA—NRF2 pathway—SLC5A5—thyroid cancer	0.000236	0.00292	CbGpPWpGaD
Bexarotene—RXRB—Generic Transcription Pathway—MEN1—thyroid cancer	0.000228	0.00282	CbGpPWpGaD
Bexarotene—CYP2C9—Metapathway biotransformation—CHST14—thyroid cancer	0.00022	0.00272	CbGpPWpGaD
Bexarotene—RXRA—Transcriptional regulation of white adipocyte differentiation—PPARG—thyroid cancer	0.000209	0.00258	CbGpPWpGaD
Bexarotene—RXRA—Generic Transcription Pathway—THRB—thyroid cancer	0.000187	0.00231	CbGpPWpGaD
Bexarotene—RXRG—neck—thyroid cancer	0.000186	0.31	CbGeAlD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000185	0.00229	CbGpPWpGaD
Bexarotene—RXRG—Gene Expression—THRB—thyroid cancer	0.000184	0.00227	CbGpPWpGaD
Bexarotene—RXRA—Retinoic acid receptors-mediated signaling—AKT1—thyroid cancer	0.000176	0.00217	CbGpPWpGaD
Bexarotene—RXRB—Gene Expression—THRB—thyroid cancer	0.000173	0.00214	CbGpPWpGaD
Bexarotene—RXRA—NRF2 pathway—NRG1—thyroid cancer	0.000172	0.00212	CbGpPWpGaD
Bexarotene—CYP3A4—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000165	0.00203	CbGpPWpGaD
Bexarotene—RXRG—Generic Transcription Pathway—RXRA—thyroid cancer	0.000162	0.002	CbGpPWpGaD
Bexarotene—RXRA—Adipogenesis—HIF1A—thyroid cancer	0.000162	0.002	CbGpPWpGaD
Bexarotene—RXRA—PPARA activates gene expression—PPARG—thyroid cancer	0.000157	0.00194	CbGpPWpGaD
Bexarotene—RXRA—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—thyroid cancer	0.000154	0.0019	CbGpPWpGaD
Bexarotene—RXRB—Generic Transcription Pathway—RXRA—thyroid cancer	0.000153	0.00188	CbGpPWpGaD
Bexarotene—CYP2C9—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000151	0.00186	CbGpPWpGaD
Bexarotene—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.00015	0.00185	CbGpPWpGaD
Bexarotene—CYP3A4—Metapathway biotransformation—CHST14—thyroid cancer	0.000145	0.00179	CbGpPWpGaD
Bexarotene—RXRA—a6b1 and a6b4 Integrin signaling—HRAS—thyroid cancer	0.000144	0.00178	CbGpPWpGaD
Bexarotene—RXRA—Adipogenesis—PPARG—thyroid cancer	0.000138	0.0017	CbGpPWpGaD
Bexarotene—Osteoarthritis—Epirubicin—thyroid cancer	0.000134	0.00087	CcSEcCtD
Bexarotene—Increased appetite—Doxorubicin—thyroid cancer	0.000132	0.000857	CcSEcCtD
Bexarotene—Migraine—Epirubicin—thyroid cancer	0.000132	0.000857	CcSEcCtD
Bexarotene—Affect lability—Epirubicin—thyroid cancer	0.000132	0.000857	CcSEcCtD
Bexarotene—Dermatitis exfoliative—Doxorubicin—thyroid cancer	0.000132	0.000853	CcSEcCtD
Bexarotene—Hypersensitivity—Sorafenib—thyroid cancer	0.000132	0.000853	CcSEcCtD
Bexarotene—Renal impairment—Doxorubicin—thyroid cancer	0.000131	0.000846	CcSEcCtD
Bexarotene—Dermatitis bullous—Doxorubicin—thyroid cancer	0.00013	0.000842	CcSEcCtD
Bexarotene—Face oedema—Epirubicin—thyroid cancer	0.00013	0.00084	CcSEcCtD
Bexarotene—Purpura—Doxorubicin—thyroid cancer	0.000129	0.000835	CcSEcCtD
Bexarotene—Asthenia—Sorafenib—thyroid cancer	0.000128	0.00083	CcSEcCtD
Bexarotene—RXRA—Metabolism—MINPP1—thyroid cancer	0.000128	0.00158	CbGpPWpGaD
Bexarotene—Mood swings—Epirubicin—thyroid cancer	0.000127	0.000824	CcSEcCtD
Bexarotene—RXRA—a6b1 and a6b4 Integrin signaling—AKT1—thyroid cancer	0.000127	0.00157	CbGpPWpGaD
Bexarotene—Lethargy—Doxorubicin—thyroid cancer	0.000127	0.000822	CcSEcCtD
Bexarotene—Cerebrovascular accident—Doxorubicin—thyroid cancer	0.000127	0.000822	CcSEcCtD
Bexarotene—Pruritus—Sorafenib—thyroid cancer	0.000127	0.000819	CcSEcCtD
Bexarotene—Ataxia—Epirubicin—thyroid cancer	0.000126	0.000818	CcSEcCtD
Bexarotene—Blood creatinine increased—Epirubicin—thyroid cancer	0.000126	0.000815	CcSEcCtD
Bexarotene—Dehydration—Epirubicin—thyroid cancer	0.000125	0.000809	CcSEcCtD
Bexarotene—Hyponatraemia—Doxorubicin—thyroid cancer	0.000125	0.000808	CcSEcCtD
Bexarotene—RXRA—Gene Expression—TRIM33—thyroid cancer	0.000125	0.00154	CbGpPWpGaD
Bexarotene—Osteoarthritis—Doxorubicin—thyroid cancer	0.000124	0.000805	CcSEcCtD
Bexarotene—RXRG—Gene Expression—TPR—thyroid cancer	0.000124	0.00153	CbGpPWpGaD
Bexarotene—Liver function test abnormal—Epirubicin—thyroid cancer	0.000124	0.000803	CcSEcCtD
Bexarotene—Dry skin—Epirubicin—thyroid cancer	0.000123	0.000798	CcSEcCtD
Bexarotene—Affect lability—Doxorubicin—thyroid cancer	0.000122	0.000793	CcSEcCtD
Bexarotene—Migraine—Doxorubicin—thyroid cancer	0.000122	0.000793	CcSEcCtD
Bexarotene—CYP2C9—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000122	0.00151	CbGpPWpGaD
Bexarotene—Hypokalaemia—Epirubicin—thyroid cancer	0.000122	0.000792	CcSEcCtD
Bexarotene—Diarrhoea—Sorafenib—thyroid cancer	0.000122	0.000792	CcSEcCtD
Bexarotene—Aspartate aminotransferase increased—Epirubicin—thyroid cancer	0.000121	0.000784	CcSEcCtD
Bexarotene—Face oedema—Doxorubicin—thyroid cancer	0.00012	0.000777	CcSEcCtD
Bexarotene—RXRA—Generic Transcription Pathway—MEN1—thyroid cancer	0.000119	0.00147	CbGpPWpGaD
Bexarotene—Alanine aminotransferase increased—Epirubicin—thyroid cancer	0.000119	0.000767	CcSEcCtD
Bexarotene—Muscular weakness—Epirubicin—thyroid cancer	0.000119	0.000767	CcSEcCtD
Bexarotene—Dizziness—Sorafenib—thyroid cancer	0.000118	0.000765	CcSEcCtD
Bexarotene—Mood swings—Doxorubicin—thyroid cancer	0.000118	0.000763	CcSEcCtD
Bexarotene—Abdominal distension—Epirubicin—thyroid cancer	0.000117	0.000757	CcSEcCtD
Bexarotene—Ataxia—Doxorubicin—thyroid cancer	0.000117	0.000757	CcSEcCtD
Bexarotene—RXRB—Gene Expression—TPR—thyroid cancer	0.000117	0.00144	CbGpPWpGaD
Bexarotene—RXRG—Gene Expression—MEN1—thyroid cancer	0.000117	0.00144	CbGpPWpGaD
Bexarotene—Blood creatinine increased—Doxorubicin—thyroid cancer	0.000117	0.000754	CcSEcCtD
Bexarotene—Influenza—Epirubicin—thyroid cancer	0.000116	0.000752	CcSEcCtD
Bexarotene—Dysphagia—Epirubicin—thyroid cancer	0.000116	0.000752	CcSEcCtD
Bexarotene—Dehydration—Doxorubicin—thyroid cancer	0.000116	0.000749	CcSEcCtD
Bexarotene—Eosinophilia—Epirubicin—thyroid cancer	0.000115	0.000745	CcSEcCtD
Bexarotene—Liver function test abnormal—Doxorubicin—thyroid cancer	0.000115	0.000743	CcSEcCtD
Bexarotene—Dry skin—Doxorubicin—thyroid cancer	0.000114	0.000738	CcSEcCtD
Bexarotene—Pancreatitis—Epirubicin—thyroid cancer	0.000114	0.000737	CcSEcCtD
Bexarotene—Vomiting—Sorafenib—thyroid cancer	0.000114	0.000736	CcSEcCtD
Bexarotene—Hypokalaemia—Doxorubicin—thyroid cancer	0.000113	0.000733	CcSEcCtD
Bexarotene—Angina pectoris—Epirubicin—thyroid cancer	0.000113	0.000733	CcSEcCtD
Bexarotene—Rash—Sorafenib—thyroid cancer	0.000113	0.00073	CcSEcCtD
Bexarotene—Dermatitis—Sorafenib—thyroid cancer	0.000113	0.000729	CcSEcCtD
Bexarotene—Aspartate aminotransferase increased—Doxorubicin—thyroid cancer	0.000112	0.000725	CcSEcCtD
Bexarotene—Headache—Sorafenib—thyroid cancer	0.000112	0.000725	CcSEcCtD
Bexarotene—Bronchitis—Epirubicin—thyroid cancer	0.000112	0.000723	CcSEcCtD
Bexarotene—Pancytopenia—Epirubicin—thyroid cancer	0.00011	0.000714	CcSEcCtD
Bexarotene—RXRB—Gene Expression—MEN1—thyroid cancer	0.00011	0.00136	CbGpPWpGaD
Bexarotene—Alanine aminotransferase increased—Doxorubicin—thyroid cancer	0.00011	0.00071	CcSEcCtD
Bexarotene—Muscular weakness—Doxorubicin—thyroid cancer	0.00011	0.00071	CcSEcCtD
Bexarotene—RXRA—Metabolism—NDUFA13—thyroid cancer	0.000109	0.00134	CbGpPWpGaD
Bexarotene—Neutropenia—Epirubicin—thyroid cancer	0.000109	0.000703	CcSEcCtD
Bexarotene—Dysuria—Epirubicin—thyroid cancer	0.000109	0.000703	CcSEcCtD
Bexarotene—Abdominal distension—Doxorubicin—thyroid cancer	0.000108	0.000701	CcSEcCtD
Bexarotene—Influenza—Doxorubicin—thyroid cancer	0.000108	0.000696	CcSEcCtD
Bexarotene—Dysphagia—Doxorubicin—thyroid cancer	0.000108	0.000696	CcSEcCtD
Bexarotene—Pollakiuria—Epirubicin—thyroid cancer	0.000107	0.000695	CcSEcCtD
Bexarotene—Eosinophilia—Doxorubicin—thyroid cancer	0.000106	0.000689	CcSEcCtD
Bexarotene—Nausea—Sorafenib—thyroid cancer	0.000106	0.000687	CcSEcCtD
Bexarotene—RXRA—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—thyroid cancer	0.000106	0.00131	CbGpPWpGaD
Bexarotene—Photosensitivity reaction—Epirubicin—thyroid cancer	0.000106	0.000686	CcSEcCtD
Bexarotene—Weight increased—Epirubicin—thyroid cancer	0.000106	0.000684	CcSEcCtD
Bexarotene—Pancreatitis—Doxorubicin—thyroid cancer	0.000105	0.000682	CcSEcCtD
Bexarotene—Weight decreased—Epirubicin—thyroid cancer	0.000105	0.00068	CcSEcCtD
Bexarotene—Hyperglycaemia—Epirubicin—thyroid cancer	0.000105	0.000678	CcSEcCtD
Bexarotene—Angina pectoris—Doxorubicin—thyroid cancer	0.000105	0.000678	CcSEcCtD
Bexarotene—Pneumonia—Epirubicin—thyroid cancer	0.000104	0.000674	CcSEcCtD
Bexarotene—Bronchitis—Doxorubicin—thyroid cancer	0.000103	0.000669	CcSEcCtD
Bexarotene—RXRG—Generic Transcription Pathway—PPARG—thyroid cancer	0.000103	0.00127	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—CHST14—thyroid cancer	0.000102	0.00126	CbGpPWpGaD
Bexarotene—Pancytopenia—Doxorubicin—thyroid cancer	0.000102	0.000661	CcSEcCtD
Bexarotene—Neuropathy peripheral—Epirubicin—thyroid cancer	0.000102	0.000657	CcSEcCtD
Bexarotene—RXRA—Transmembrane transport of small molecules—CP—thyroid cancer	0.000101	0.00125	CbGpPWpGaD
Bexarotene—RXRA—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000101	0.00125	CbGpPWpGaD
Bexarotene—Stomatitis—Epirubicin—thyroid cancer	0.000101	0.000654	CcSEcCtD
Bexarotene—Jaundice—Epirubicin—thyroid cancer	0.000101	0.000654	CcSEcCtD
Bexarotene—Conjunctivitis—Epirubicin—thyroid cancer	0.000101	0.000652	CcSEcCtD
Bexarotene—Urinary tract infection—Epirubicin—thyroid cancer	0.000101	0.000652	CcSEcCtD
Bexarotene—Neutropenia—Doxorubicin—thyroid cancer	0.000101	0.000651	CcSEcCtD
Bexarotene—Dysuria—Doxorubicin—thyroid cancer	0.000101	0.000651	CcSEcCtD
Bexarotene—CYP3A4—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	9.96e-05	0.00123	CbGpPWpGaD
Bexarotene—RXRA—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	9.95e-05	0.00123	CbGpPWpGaD
Bexarotene—Sweating—Epirubicin—thyroid cancer	9.94e-05	0.000643	CcSEcCtD
Bexarotene—Pollakiuria—Doxorubicin—thyroid cancer	9.94e-05	0.000643	CcSEcCtD
Bexarotene—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	9.91e-05	0.00122	CbGpPWpGaD
Bexarotene—Haematuria—Epirubicin—thyroid cancer	9.88e-05	0.000639	CcSEcCtD
Bexarotene—Photosensitivity reaction—Doxorubicin—thyroid cancer	9.82e-05	0.000635	CcSEcCtD
Bexarotene—Weight increased—Doxorubicin—thyroid cancer	9.79e-05	0.000633	CcSEcCtD
Bexarotene—Epistaxis—Epirubicin—thyroid cancer	9.78e-05	0.000633	CcSEcCtD
Bexarotene—Weight decreased—Doxorubicin—thyroid cancer	9.73e-05	0.00063	CcSEcCtD
Bexarotene—Sinusitis—Epirubicin—thyroid cancer	9.72e-05	0.000629	CcSEcCtD
Bexarotene—Hyperglycaemia—Doxorubicin—thyroid cancer	9.7e-05	0.000628	CcSEcCtD
Bexarotene—Pneumonia—Doxorubicin—thyroid cancer	9.65e-05	0.000624	CcSEcCtD
Bexarotene—RXRB—Generic Transcription Pathway—PPARG—thyroid cancer	9.64e-05	0.00119	CbGpPWpGaD
Bexarotene—Neuropathy peripheral—Doxorubicin—thyroid cancer	9.4e-05	0.000608	CcSEcCtD
Bexarotene—Haemoglobin—Epirubicin—thyroid cancer	9.35e-05	0.000605	CcSEcCtD
Bexarotene—Jaundice—Doxorubicin—thyroid cancer	9.35e-05	0.000605	CcSEcCtD
Bexarotene—Stomatitis—Doxorubicin—thyroid cancer	9.35e-05	0.000605	CcSEcCtD
Bexarotene—Rhinitis—Epirubicin—thyroid cancer	9.33e-05	0.000604	CcSEcCtD
Bexarotene—Urinary tract infection—Doxorubicin—thyroid cancer	9.32e-05	0.000603	CcSEcCtD
Bexarotene—Conjunctivitis—Doxorubicin—thyroid cancer	9.32e-05	0.000603	CcSEcCtD
Bexarotene—Haemorrhage—Epirubicin—thyroid cancer	9.3e-05	0.000602	CcSEcCtD
Bexarotene—Hypoaesthesia—Epirubicin—thyroid cancer	9.26e-05	0.000599	CcSEcCtD
Bexarotene—Pharyngitis—Epirubicin—thyroid cancer	9.23e-05	0.000597	CcSEcCtD
Bexarotene—Sweating—Doxorubicin—thyroid cancer	9.19e-05	0.000595	CcSEcCtD
Bexarotene—Urinary tract disorder—Epirubicin—thyroid cancer	9.19e-05	0.000594	CcSEcCtD
Bexarotene—Oedema peripheral—Epirubicin—thyroid cancer	9.17e-05	0.000593	CcSEcCtD
Bexarotene—Haematuria—Doxorubicin—thyroid cancer	9.14e-05	0.000592	CcSEcCtD
Bexarotene—Connective tissue disorder—Epirubicin—thyroid cancer	9.14e-05	0.000592	CcSEcCtD
Bexarotene—Urethral disorder—Epirubicin—thyroid cancer	9.12e-05	0.00059	CcSEcCtD
Bexarotene—Epistaxis—Doxorubicin—thyroid cancer	9.04e-05	0.000585	CcSEcCtD
Bexarotene—RXRA—Gene Expression—THRB—thyroid cancer	9.02e-05	0.00111	CbGpPWpGaD
Bexarotene—Sinusitis—Doxorubicin—thyroid cancer	9e-05	0.000582	CcSEcCtD
Bexarotene—RXRA—head—thyroid cancer	8.95e-05	0.149	CbGeAlD
Bexarotene—RXRG—thyroid gland—thyroid cancer	8.86e-05	0.148	CbGeAlD
Bexarotene—Eye disorder—Epirubicin—thyroid cancer	8.69e-05	0.000563	CcSEcCtD
Bexarotene—CYP2C9—Arachidonic acid metabolism—PTGS2—thyroid cancer	8.68e-05	0.00107	CbGpPWpGaD
Bexarotene—Tinnitus—Epirubicin—thyroid cancer	8.67e-05	0.000561	CcSEcCtD
Bexarotene—Haemoglobin—Doxorubicin—thyroid cancer	8.65e-05	0.00056	CcSEcCtD
Bexarotene—Cardiac disorder—Epirubicin—thyroid cancer	8.63e-05	0.000559	CcSEcCtD
Bexarotene—Rhinitis—Doxorubicin—thyroid cancer	8.63e-05	0.000558	CcSEcCtD
Bexarotene—Haemorrhage—Doxorubicin—thyroid cancer	8.61e-05	0.000557	CcSEcCtD
Bexarotene—Hypoaesthesia—Doxorubicin—thyroid cancer	8.57e-05	0.000554	CcSEcCtD
Bexarotene—Pharyngitis—Doxorubicin—thyroid cancer	8.54e-05	0.000553	CcSEcCtD
Bexarotene—Urinary tract disorder—Doxorubicin—thyroid cancer	8.5e-05	0.00055	CcSEcCtD
Bexarotene—Oedema peripheral—Doxorubicin—thyroid cancer	8.48e-05	0.000549	CcSEcCtD
Bexarotene—Connective tissue disorder—Doxorubicin—thyroid cancer	8.46e-05	0.000547	CcSEcCtD
Bexarotene—Angiopathy—Epirubicin—thyroid cancer	8.44e-05	0.000546	CcSEcCtD
Bexarotene—Urethral disorder—Doxorubicin—thyroid cancer	8.44e-05	0.000546	CcSEcCtD
Bexarotene—Chills—Epirubicin—thyroid cancer	8.35e-05	0.00054	CcSEcCtD
Bexarotene—RXRB—thyroid gland—thyroid cancer	8.33e-05	0.139	CbGeAlD
Bexarotene—Arrhythmia—Epirubicin—thyroid cancer	8.31e-05	0.000538	CcSEcCtD
Bexarotene—RXRA—Metabolism—HPGD—thyroid cancer	8.25e-05	0.00102	CbGpPWpGaD
Bexarotene—Alopecia—Epirubicin—thyroid cancer	8.22e-05	0.000532	CcSEcCtD
Bexarotene—Erythema—Epirubicin—thyroid cancer	8.1e-05	0.000524	CcSEcCtD
Bexarotene—Malnutrition—Epirubicin—thyroid cancer	8.1e-05	0.000524	CcSEcCtD
Bexarotene—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	8.08e-05	0.000997	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—CDK1—thyroid cancer	8.07e-05	0.000996	CbGpPWpGaD
Bexarotene—Eye disorder—Doxorubicin—thyroid cancer	8.04e-05	0.000521	CcSEcCtD
Bexarotene—Tinnitus—Doxorubicin—thyroid cancer	8.03e-05	0.000519	CcSEcCtD
Bexarotene—Cardiac disorder—Doxorubicin—thyroid cancer	7.99e-05	0.000517	CcSEcCtD
Bexarotene—Flatulence—Epirubicin—thyroid cancer	7.98e-05	0.000516	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	7.96e-05	0.000982	CbGpPWpGaD
Bexarotene—Tension—Epirubicin—thyroid cancer	7.95e-05	0.000514	CcSEcCtD
Bexarotene—Dysgeusia—Epirubicin—thyroid cancer	7.93e-05	0.000513	CcSEcCtD
Bexarotene—Nervousness—Epirubicin—thyroid cancer	7.87e-05	0.000509	CcSEcCtD
Bexarotene—RXRG—head—thyroid cancer	7.86e-05	0.131	CbGeAlD
Bexarotene—Back pain—Epirubicin—thyroid cancer	7.83e-05	0.000507	CcSEcCtD
Bexarotene—RXRG—Gene Expression—RXRA—thyroid cancer	7.82e-05	0.000965	CbGpPWpGaD
Bexarotene—Angiopathy—Doxorubicin—thyroid cancer	7.81e-05	0.000505	CcSEcCtD
Bexarotene—Muscle spasms—Epirubicin—thyroid cancer	7.79e-05	0.000504	CcSEcCtD
Bexarotene—Chills—Doxorubicin—thyroid cancer	7.72e-05	0.0005	CcSEcCtD
Bexarotene—Arrhythmia—Doxorubicin—thyroid cancer	7.69e-05	0.000498	CcSEcCtD
Bexarotene—Alopecia—Doxorubicin—thyroid cancer	7.61e-05	0.000492	CcSEcCtD
Bexarotene—RXRA—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	7.57e-05	0.000935	CbGpPWpGaD
Bexarotene—Ill-defined disorder—Epirubicin—thyroid cancer	7.51e-05	0.000486	CcSEcCtD
Bexarotene—Malnutrition—Doxorubicin—thyroid cancer	7.49e-05	0.000485	CcSEcCtD
Bexarotene—Erythema—Doxorubicin—thyroid cancer	7.49e-05	0.000485	CcSEcCtD
Bexarotene—Anaemia—Epirubicin—thyroid cancer	7.49e-05	0.000484	CcSEcCtD
Bexarotene—Agitation—Epirubicin—thyroid cancer	7.44e-05	0.000482	CcSEcCtD
Bexarotene—RXRB—head—thyroid cancer	7.39e-05	0.123	CbGeAlD
Bexarotene—Flatulence—Doxorubicin—thyroid cancer	7.38e-05	0.000478	CcSEcCtD
Bexarotene—RXRB—Gene Expression—RXRA—thyroid cancer	7.35e-05	0.000908	CbGpPWpGaD
Bexarotene—Tension—Doxorubicin—thyroid cancer	7.35e-05	0.000476	CcSEcCtD
Bexarotene—Dysgeusia—Doxorubicin—thyroid cancer	7.34e-05	0.000475	CcSEcCtD
Bexarotene—Malaise—Epirubicin—thyroid cancer	7.3e-05	0.000473	CcSEcCtD
Bexarotene—Nervousness—Doxorubicin—thyroid cancer	7.28e-05	0.000471	CcSEcCtD
Bexarotene—Vertigo—Epirubicin—thyroid cancer	7.28e-05	0.000471	CcSEcCtD
Bexarotene—Syncope—Epirubicin—thyroid cancer	7.26e-05	0.00047	CcSEcCtD
Bexarotene—Leukopenia—Epirubicin—thyroid cancer	7.25e-05	0.000469	CcSEcCtD
Bexarotene—Back pain—Doxorubicin—thyroid cancer	7.25e-05	0.000469	CcSEcCtD
Bexarotene—Muscle spasms—Doxorubicin—thyroid cancer	7.2e-05	0.000466	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	7.19e-05	0.000888	CbGpPWpGaD
Bexarotene—Palpitations—Epirubicin—thyroid cancer	7.16e-05	0.000463	CcSEcCtD
Bexarotene—Loss of consciousness—Epirubicin—thyroid cancer	7.12e-05	0.000461	CcSEcCtD
Bexarotene—Cough—Epirubicin—thyroid cancer	7.07e-05	0.000457	CcSEcCtD
Bexarotene—Hypertension—Epirubicin—thyroid cancer	6.99e-05	0.000452	CcSEcCtD
Bexarotene—Ill-defined disorder—Doxorubicin—thyroid cancer	6.95e-05	0.00045	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	6.94e-05	0.000857	CbGpPWpGaD
Bexarotene—Anaemia—Doxorubicin—thyroid cancer	6.93e-05	0.000448	CcSEcCtD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	6.92e-05	0.000853	CbGpPWpGaD
Bexarotene—Chest pain—Epirubicin—thyroid cancer	6.9e-05	0.000446	CcSEcCtD
Bexarotene—Myalgia—Epirubicin—thyroid cancer	6.9e-05	0.000446	CcSEcCtD
Bexarotene—Arthralgia—Epirubicin—thyroid cancer	6.9e-05	0.000446	CcSEcCtD
Bexarotene—Agitation—Doxorubicin—thyroid cancer	6.89e-05	0.000446	CcSEcCtD
Bexarotene—Anxiety—Epirubicin—thyroid cancer	6.87e-05	0.000445	CcSEcCtD
Bexarotene—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	6.85e-05	0.000443	CcSEcCtD
Bexarotene—Discomfort—Epirubicin—thyroid cancer	6.81e-05	0.000441	CcSEcCtD
Bexarotene—Malaise—Doxorubicin—thyroid cancer	6.76e-05	0.000437	CcSEcCtD
Bexarotene—Dry mouth—Epirubicin—thyroid cancer	6.74e-05	0.000436	CcSEcCtD
Bexarotene—Vertigo—Doxorubicin—thyroid cancer	6.73e-05	0.000436	CcSEcCtD
Bexarotene—Syncope—Doxorubicin—thyroid cancer	6.72e-05	0.000435	CcSEcCtD
Bexarotene—Leukopenia—Doxorubicin—thyroid cancer	6.71e-05	0.000434	CcSEcCtD
Bexarotene—Confusional state—Epirubicin—thyroid cancer	6.66e-05	0.000431	CcSEcCtD
Bexarotene—Palpitations—Doxorubicin—thyroid cancer	6.62e-05	0.000428	CcSEcCtD
Bexarotene—Oedema—Epirubicin—thyroid cancer	6.61e-05	0.000428	CcSEcCtD
Bexarotene—Loss of consciousness—Doxorubicin—thyroid cancer	6.59e-05	0.000426	CcSEcCtD
Bexarotene—Infection—Epirubicin—thyroid cancer	6.57e-05	0.000425	CcSEcCtD
Bexarotene—Cough—Doxorubicin—thyroid cancer	6.54e-05	0.000423	CcSEcCtD
Bexarotene—CYP2C9—Biological oxidations—RXRA—thyroid cancer	6.51e-05	0.000803	CbGpPWpGaD
Bexarotene—Shock—Epirubicin—thyroid cancer	6.5e-05	0.000421	CcSEcCtD
Bexarotene—Nervous system disorder—Epirubicin—thyroid cancer	6.48e-05	0.000419	CcSEcCtD
Bexarotene—Thrombocytopenia—Epirubicin—thyroid cancer	6.47e-05	0.000419	CcSEcCtD
Bexarotene—Hypertension—Doxorubicin—thyroid cancer	6.47e-05	0.000419	CcSEcCtD
Bexarotene—Tachycardia—Epirubicin—thyroid cancer	6.45e-05	0.000417	CcSEcCtD
Bexarotene—Skin disorder—Epirubicin—thyroid cancer	6.42e-05	0.000415	CcSEcCtD
Bexarotene—Hyperhidrosis—Epirubicin—thyroid cancer	6.39e-05	0.000413	CcSEcCtD
Bexarotene—Chest pain—Doxorubicin—thyroid cancer	6.38e-05	0.000413	CcSEcCtD
Bexarotene—Arthralgia—Doxorubicin—thyroid cancer	6.38e-05	0.000413	CcSEcCtD
Bexarotene—Myalgia—Doxorubicin—thyroid cancer	6.38e-05	0.000413	CcSEcCtD
Bexarotene—Anxiety—Doxorubicin—thyroid cancer	6.36e-05	0.000411	CcSEcCtD
Bexarotene—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	6.34e-05	0.00041	CcSEcCtD
Bexarotene—Discomfort—Doxorubicin—thyroid cancer	6.3e-05	0.000408	CcSEcCtD
Bexarotene—Anorexia—Epirubicin—thyroid cancer	6.3e-05	0.000408	CcSEcCtD
Bexarotene—Dry mouth—Doxorubicin—thyroid cancer	6.24e-05	0.000404	CcSEcCtD
Bexarotene—Confusional state—Doxorubicin—thyroid cancer	6.17e-05	0.000399	CcSEcCtD
Bexarotene—Oedema—Doxorubicin—thyroid cancer	6.12e-05	0.000396	CcSEcCtD
Bexarotene—RXRA—Gene Expression—TPR—thyroid cancer	6.09e-05	0.000752	CbGpPWpGaD
Bexarotene—Infection—Doxorubicin—thyroid cancer	6.08e-05	0.000393	CcSEcCtD
Bexarotene—Musculoskeletal discomfort—Epirubicin—thyroid cancer	6.02e-05	0.00039	CcSEcCtD
Bexarotene—Shock—Doxorubicin—thyroid cancer	6.02e-05	0.000389	CcSEcCtD
Bexarotene—Nervous system disorder—Doxorubicin—thyroid cancer	6e-05	0.000388	CcSEcCtD
Bexarotene—Thrombocytopenia—Doxorubicin—thyroid cancer	5.99e-05	0.000387	CcSEcCtD
Bexarotene—Insomnia—Epirubicin—thyroid cancer	5.98e-05	0.000387	CcSEcCtD
Bexarotene—Tachycardia—Doxorubicin—thyroid cancer	5.97e-05	0.000386	CcSEcCtD
Bexarotene—Skin disorder—Doxorubicin—thyroid cancer	5.94e-05	0.000384	CcSEcCtD
Bexarotene—Paraesthesia—Epirubicin—thyroid cancer	5.94e-05	0.000384	CcSEcCtD
Bexarotene—Hyperhidrosis—Doxorubicin—thyroid cancer	5.91e-05	0.000383	CcSEcCtD
Bexarotene—Dyspnoea—Epirubicin—thyroid cancer	5.89e-05	0.000381	CcSEcCtD
Bexarotene—Somnolence—Epirubicin—thyroid cancer	5.88e-05	0.00038	CcSEcCtD
Bexarotene—Anorexia—Doxorubicin—thyroid cancer	5.83e-05	0.000377	CcSEcCtD
Bexarotene—Dyspepsia—Epirubicin—thyroid cancer	5.82e-05	0.000376	CcSEcCtD
Bexarotene—Decreased appetite—Epirubicin—thyroid cancer	5.75e-05	0.000372	CcSEcCtD
Bexarotene—RXRA—Gene Expression—MEN1—thyroid cancer	5.73e-05	0.000707	CbGpPWpGaD
Bexarotene—Gastrointestinal disorder—Epirubicin—thyroid cancer	5.71e-05	0.000369	CcSEcCtD
Bexarotene—Fatigue—Epirubicin—thyroid cancer	5.7e-05	0.000369	CcSEcCtD
Bexarotene—Pain—Epirubicin—thyroid cancer	5.65e-05	0.000366	CcSEcCtD
Bexarotene—Constipation—Epirubicin—thyroid cancer	5.65e-05	0.000366	CcSEcCtD
Bexarotene—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	5.57e-05	0.000361	CcSEcCtD
Bexarotene—Insomnia—Doxorubicin—thyroid cancer	5.53e-05	0.000358	CcSEcCtD
Bexarotene—Paraesthesia—Doxorubicin—thyroid cancer	5.49e-05	0.000355	CcSEcCtD
Bexarotene—Dyspnoea—Doxorubicin—thyroid cancer	5.45e-05	0.000353	CcSEcCtD
Bexarotene—Feeling abnormal—Epirubicin—thyroid cancer	5.45e-05	0.000352	CcSEcCtD
Bexarotene—Somnolence—Doxorubicin—thyroid cancer	5.44e-05	0.000352	CcSEcCtD
Bexarotene—Gastrointestinal pain—Epirubicin—thyroid cancer	5.41e-05	0.00035	CcSEcCtD
Bexarotene—Dyspepsia—Doxorubicin—thyroid cancer	5.38e-05	0.000348	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	5.33e-05	0.000658	CbGpPWpGaD
Bexarotene—Decreased appetite—Doxorubicin—thyroid cancer	5.32e-05	0.000344	CcSEcCtD
Bexarotene—Gastrointestinal disorder—Doxorubicin—thyroid cancer	5.28e-05	0.000342	CcSEcCtD
Bexarotene—Fatigue—Doxorubicin—thyroid cancer	5.27e-05	0.000341	CcSEcCtD
Bexarotene—Constipation—Doxorubicin—thyroid cancer	5.23e-05	0.000338	CcSEcCtD
Bexarotene—Pain—Doxorubicin—thyroid cancer	5.23e-05	0.000338	CcSEcCtD
Bexarotene—Abdominal pain—Epirubicin—thyroid cancer	5.23e-05	0.000338	CcSEcCtD
Bexarotene—Body temperature increased—Epirubicin—thyroid cancer	5.23e-05	0.000338	CcSEcCtD
Bexarotene—Feeling abnormal—Doxorubicin—thyroid cancer	5.04e-05	0.000326	CcSEcCtD
Bexarotene—RXRA—Generic Transcription Pathway—PPARG—thyroid cancer	5.03e-05	0.00062	CbGpPWpGaD
Bexarotene—Gastrointestinal pain—Doxorubicin—thyroid cancer	5e-05	0.000324	CcSEcCtD
Bexarotene—RXRG—Gene Expression—PPARG—thyroid cancer	4.94e-05	0.000609	CbGpPWpGaD
Bexarotene—Hypersensitivity—Epirubicin—thyroid cancer	4.87e-05	0.000315	CcSEcCtD
Bexarotene—Body temperature increased—Doxorubicin—thyroid cancer	4.83e-05	0.000313	CcSEcCtD
Bexarotene—Abdominal pain—Doxorubicin—thyroid cancer	4.83e-05	0.000313	CcSEcCtD
Bexarotene—CYP2C9—Metabolism—MINPP1—thyroid cancer	4.78e-05	0.00059	CbGpPWpGaD
Bexarotene—Asthenia—Epirubicin—thyroid cancer	4.74e-05	0.000307	CcSEcCtD
Bexarotene—RXRA—Metabolism—TPR—thyroid cancer	4.74e-05	0.000585	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	4.74e-05	0.000585	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—PPARG—thyroid cancer	4.73e-05	0.000584	CbGpPWpGaD
Bexarotene—Pruritus—Epirubicin—thyroid cancer	4.68e-05	0.000303	CcSEcCtD
Bexarotene—RXRA—Metabolism—PRKAR1A—thyroid cancer	4.66e-05	0.000575	CbGpPWpGaD
Bexarotene—RXRB—Gene Expression—PPARG—thyroid cancer	4.64e-05	0.000573	CbGpPWpGaD
Bexarotene—Diarrhoea—Epirubicin—thyroid cancer	4.52e-05	0.000293	CcSEcCtD
Bexarotene—Hypersensitivity—Doxorubicin—thyroid cancer	4.51e-05	0.000292	CcSEcCtD
Bexarotene—Asthenia—Doxorubicin—thyroid cancer	4.39e-05	0.000284	CcSEcCtD
Bexarotene—Dizziness—Epirubicin—thyroid cancer	4.37e-05	0.000283	CcSEcCtD
Bexarotene—Pruritus—Doxorubicin—thyroid cancer	4.33e-05	0.00028	CcSEcCtD
Bexarotene—CYP3A4—Biological oxidations—RXRA—thyroid cancer	4.29e-05	0.000529	CbGpPWpGaD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	4.23e-05	0.000521	CbGpPWpGaD
Bexarotene—Vomiting—Epirubicin—thyroid cancer	4.2e-05	0.000272	CcSEcCtD
Bexarotene—Diarrhoea—Doxorubicin—thyroid cancer	4.18e-05	0.000271	CcSEcCtD
Bexarotene—Rash—Epirubicin—thyroid cancer	4.17e-05	0.00027	CcSEcCtD
Bexarotene—Dermatitis—Epirubicin—thyroid cancer	4.16e-05	0.000269	CcSEcCtD
Bexarotene—Headache—Epirubicin—thyroid cancer	4.14e-05	0.000268	CcSEcCtD
Bexarotene—CYP2C9—Metabolism—NDUFA13—thyroid cancer	4.06e-05	0.000502	CbGpPWpGaD
Bexarotene—Dizziness—Doxorubicin—thyroid cancer	4.04e-05	0.000262	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	4e-05	0.000494	CbGpPWpGaD
Bexarotene—Nausea—Epirubicin—thyroid cancer	3.93e-05	0.000254	CcSEcCtD
Bexarotene—Vomiting—Doxorubicin—thyroid cancer	3.89e-05	0.000252	CcSEcCtD
Bexarotene—Rash—Doxorubicin—thyroid cancer	3.86e-05	0.00025	CcSEcCtD
Bexarotene—Dermatitis—Doxorubicin—thyroid cancer	3.85e-05	0.000249	CcSEcCtD
Bexarotene—Headache—Doxorubicin—thyroid cancer	3.83e-05	0.000248	CcSEcCtD
Bexarotene—CYP2C9—Metabolism—CHST14—thyroid cancer	3.82e-05	0.000472	CbGpPWpGaD
Bexarotene—Nausea—Doxorubicin—thyroid cancer	3.63e-05	0.000235	CcSEcCtD
Bexarotene—RXRA—Metabolism—SLC5A5—thyroid cancer	3.55e-05	0.000438	CbGpPWpGaD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	3.32e-05	0.00041	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—MINPP1—thyroid cancer	3.15e-05	0.000389	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—HPGD—thyroid cancer	3.08e-05	0.00038	CbGpPWpGaD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	2.9e-05	0.000358	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—NRAS—thyroid cancer	2.9e-05	0.000357	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—NDUFA13—thyroid cancer	2.68e-05	0.000331	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—CHST14—thyroid cancer	2.52e-05	0.000311	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	2.5e-05	0.000308	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—KRAS—thyroid cancer	2.49e-05	0.000308	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—PPARG—thyroid cancer	2.42e-05	0.000299	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—HRAS—thyroid cancer	2.12e-05	0.000261	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—HPGD—thyroid cancer	2.03e-05	0.000251	CbGpPWpGaD
Bexarotene—RXRG—Gene Expression—AKT1—thyroid cancer	1.95e-05	0.000241	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—PPARG—thyroid cancer	1.88e-05	0.000232	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—AKT1—thyroid cancer	1.87e-05	0.000231	CbGpPWpGaD
Bexarotene—RXRB—Gene Expression—AKT1—thyroid cancer	1.84e-05	0.000227	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—TPR—thyroid cancer	1.77e-05	0.000218	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—PRKAR1A—thyroid cancer	1.74e-05	0.000215	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	1.58e-05	0.000195	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—PTGS2—thyroid cancer	1.48e-05	0.000183	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—SLC5A5—thyroid cancer	1.32e-05	0.000163	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—PTEN—thyroid cancer	1.29e-05	0.000159	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.24e-05	0.000153	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—TPR—thyroid cancer	1.17e-05	0.000144	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	1.15e-05	0.000142	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—RXRA—thyroid cancer	1.11e-05	0.000137	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.08e-05	0.000134	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—AKT1—thyroid cancer	9.57e-06	0.000118	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—SLC5A5—thyroid cancer	8.73e-06	0.000108	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—AKT1—thyroid cancer	7.44e-06	9.18e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—RXRA—thyroid cancer	7.34e-06	9.06e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—PPARG—thyroid cancer	7.03e-06	8.67e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—PTGS2—thyroid cancer	5.53e-06	6.82e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—PTEN—thyroid cancer	4.82e-06	5.95e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—PPARG—thyroid cancer	4.63e-06	5.72e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—PTGS2—thyroid cancer	3.64e-06	4.5e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—PTEN—thyroid cancer	3.18e-06	3.92e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—AKT1—thyroid cancer	2.78e-06	3.43e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—AKT1—thyroid cancer	1.83e-06	2.26e-05	CbGpPWpGaD
